The Leonardo International Award goes to Eli Lilly
[ad_1]
On the occasion of the National Day of Made in Italy which is celebrated today, this morning the Leonardo Awards: awards that are given every year to entrepreneurs who are “ambassadors of Italian quality in the world”. Among these there is also the Leonardo International Award, dedicated to those who have contributed to developing and improving the cultural and economic ties of another country with Italy. And the 2024 edition was awarded to the US pharmaceutical company Eli Lilly, with these reasons: “For its historic commitment to the research, development and production of innovative medicines in Italy, where it has been based for 65 years, generating economic value , occupational and cognitive for Italy with attention to environmental sustainability, generating innovation in the life sciences sector”. It is the first time that the recognition has been given to a foreign-invested pharmaceutical company.
From Indianapolis to Sesto Fiorentino
The company was founded in Indianapolis in 1876, marketed the world’s first insulin over 100 years ago, and contributed to Italian industrial development with approximately 1.5 billion in investments over the last 20 years. Furthermore, by 2025, it has announced a new commitment in Italy of over 750 million to strengthen the production of innovative medicines, with a specific focus on therapies for the treatment of diabetes and obesity. According to a study by the European House Ambrosetti, Lilly will contribute 1.5 billion euros to the Italian GDP by 2025, creating over 6,000 jobs in the country. “We are proud of this important recognition, which attests to Eli Lilly’s great commitment in Italy – stated Ilya Yuffa, President of Lilly International, who accepted the Award – Guided by science, innovation and our values, we are increasingly focused on developing innovative solutions in therapeutic areas crucial to public health, including diabetes and obesity, cancer, autoimmune diseases and neurodegenerative diseases such as Alzheimer’s. In the coming years we want to further strengthen our presence in the country, which is at the center of our global growth strategy.”
For over 65 years in Italy
The ceremony took place this morning in the Senate, and the Awards were presented by President Ignazio La Russa together with the Vice President of the Council of Ministers and Minister of Foreign Affairs and International Cooperation Antonio Tajani, the Minister of Business and Made in Italy Adolfo Urso and to the President of the Leonardo Committee, as well as Executive President of Dompé Farmaceutici, Sergio Dompé. “The International Award to Eli Lilly is an excellent signal for Made in Italy and a due recognition – commented Dompé – The US company is one of the pharmaceutical pioneers present in Italy for over 65 years, where it has been able to bring expertise and therapeutic solutions innovative, producing exports to the whole world for 95% of production”.
In Sesto Fiorentino, where Lilly settled in 1959, a plant was built for the production of innovative biotechnological drugs, intended for the production of insulin from recombinant DNA for European and non-European countries. Overall, the hub guarantees diabetes medicines to more than 7 million patients every year in over 60 countries around the world. Furthermore, in 2023, again in Sesto Fiorentino, a new energy trigenerator was inaugurated with an investment of over 9 million euros which, combined with the strengthening of the photovoltaic systems already installed in the production site, will support the achievement of the global carbon target neutrality by 2030. “The Sesto Fiorentino industrial site is one of the largest in Italy and is a center of international excellence – commented Marcello Cattani, President of Farmindustria – With an eye towards the future and a strong propensity for innovation, to production and exports, Eli Lilly makes a fundamental contribution to the care of many citizens. And at the same time to the growth of qualified employment, including many young people and women, and of the economy of the region and of our entire nation”.
The pipeline and clinical studies in Italy
Eli Lilly is today the first pharmaceutical company in the world by capitalization. Its pipeline today includes over 70 new potential products and 4 new drugs launched globally in 2023. “Our commitment in Italy has a strategic role – underlined Yuffa – Here we find the high-level skills and professionalism to continue to collaborate for the development of new drugs and help more and more patients around the world. Lilly in Italy also focuses on Research and Development, with investments in this area 5.4 times higher than the manufacturing sector average and over 50 clinical studies currently active throughout the country. We have expanded our pipeline to new therapeutic areas, which have significant importance for many patients – he concluded – Our goal is to provide answers to therapeutic needs that are still unmet and actively contribute to the promotion of a more efficient, resilient and sustainable healthcare system” .
[ad_2]
Source link
